Clinical Trials: An Overview of Rescue Clinical Trials
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Since 2010, the greatest annual number of rescue clinical trials occurred in 2018, with 7,657 clinical trials. Phase II outnumbered all other phases, making up to more than 40% of trials; all others were below 20%. Non-industry sponsors had the largest share of rescue clinical trials with over 60%. Single-country trials greatly outnumber multinational trials at more than 75%. North America leads single-country trials, followed by Asia-Pacific, Europe, the Middle East and Africa, and South and Central America. Europe has the most multinational clinical trials, followed by North America, Asia-Pacific, the Middle East & Africa, and South & Central America.
Oncology and indications under its umbrella such as blood cancer, gastrointestinal tract cancer, and lung cancer were the top therapy area and indications tested in rescue clinical trials. Oncology also had the highest percentage of rescue clinical trials to overall trials since 2010. Pembrolizumab was the top drug tested in rescue clinical trials, with the most in ongoing trials. Novartis and National Cancer Institute US are found to be the top sponsors for rescue clinical trials by delayed start date, while GlaxoSmithKline and University of Texas MD Anderson Cancer Center are the top sponsors for rescue clinical trials by delayed end date.
What are the market dynamics of the global rescue clinical trials sector?
When looking at these trials by status, most trials are completed, with over 60% increase from completed for rescue clinical trials by delayed estimated start date. It is expected that there would be little to no planned clinical trials since they have not yet started, and therefore could not have delayed their end dates. Phase II greatly outnumbered all other phases for rescue clinical trials by the delayed estimated end date, making up to more than 40%. Phase I, Phase III, and Phase IV followed up with more than 15%. These are also very similar to those with delayed estimated start dates.
Rescue clinical trials by delayed start date have increased over time since 2010, with the biggest increase seen between 2015 and 2016. Trials with delayed end date increased steadily until plateauing in 2015, and then slowly declined with 2021 having the fewest trials. This may be due to many of the original set end dates not passing and being changed to a new date. The top industry sponsor during this time was GlaxoSmithKline while University of Texas MD Anderson Cancer Center was the top non-industry sponsor.
What are the top regions and countries in the global rescue clinical trials sector?
Like rescue clinical trials by estimated delayed start date, North America has the most overall single-country rescue clinical trial by the delayed estimated end date, with 16,825 trials. This region has the most in all phases, with over 8,000 in Phase II. Europe, Asia-Pacific, Middle East & Africa, and South and Central America follow. Europe has the most multinational clinical trials. North America, the region that has the most single country trials, has the second most multinational trials, followed by Asia-Pacific, the Middle East & Africa, and South and Central America.
When looking at phases, Europe has the most Phase II, Phase III, and Phase IV trials while North America has the most in Phase I. Region statistics for rescue clinical trials by delayed estimated end date are very similar to those with delayed estimated start date, showing no major advantages and/or disadvantages based on location.
Single-country rescue clinical trials by delayed estimated start date, by regions
For more regional insights, download a free report sample
Which are the key companies in the global rescue clinical trials sector?
The top industry sponsor for rescue clinical trials by delayed estimated start date was Novartis with 345 trials. Other major sponsors include GlaxoSmithKline, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Pfizer, AstraZeneca, Eli Lilly, Merck, and Boehringer Ingelheim International.
Global rescue clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key therapy area | Oncology, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, Respiratory, Musculoskeletal Disorder, Cardiovascular, and Metabolic Disorders |
Key companies | Novartis, GlaxoSmithKline, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Pfizer, AstraZeneca, Eli Lilly, Merck, and Boehringer Ingelheim International. |
Scope
The clinical trials data used for these analyses were extracted from Global Data’s Clinical Trials Database. The data included clinical trials since 2010, which were captured in the database as of October 28, 2021. The trials were analysed and segmented by all rescue clinical trials, trials with delayed estimated start date, and trials with delayed estimated end date. Further analysis was conducted based on phase, status, multinational vs. single country, sponsor type, top industry and non-industry sponsors, trials utilizing CROs, virtual components, therapy area, and drugs. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
Reasons to Buy
- Understand the rescue trials landscape.
- The trends of rescue clinical trials with delayed estimated start date.
- The trends of rescue clinical trials with delayed estimated end date.
Table of Contents
Figures
Frequently asked questions
-
What are the key therapy areas in the global rescue clinical trials sector?
The key therapy areas in the global rescue clinical trials sector are oncology, hematological disorders, gastrointestinal, immunology, infectious disease, respiratory, musculoskeletal disorder, cardiovascular, and metabolic disorders.
-
Which are the key companies in the global rescue clinical trials sector?
The key companies are Novartis, GlaxoSmithKline, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Pfizer, AstraZeneca, Eli Lilly, Merck, and Boehringer Ingelheim International.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.